- Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin PharmaceuticalNASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller
Mueller described BioMarin as one of the largest rare-disease-focused biopharmaceutical companies, with more than 25 years of operating history, six first-in-disease medicines and nine approved therapies. The company operates in more than 80 countries and expects revenue approaching $4 billion this year, he said
Get BMRN alerts:
- 3 Oversold Stocks with Big RSI Rebound Potential
The company’s strategy centers on genetically defined <a href="https://healthylife7.com/pittsburgh-set-to-become-rare-disease-research-hub-with-25m-investment/" title="Pittsburgh set to become rare disease research hub with $25M investment”>rare diseases, where BioMarin seeks to identify the underlying genetic cause of a condition and develop precision medicines targeted at that cause. Mueller said that approach can support smaller clinical studies, regulatory incentives and strong engagement with patient advocacy communities
Quarterly Performance and Amicus Integration
BioMarin reported nearly $1 billion in second-quarter revenue, representing 20% year-over-year growth, Mueller said. The company raised total-revenue guidance to a range of $3.875 billion to $3.925 billion and raised non-GAAP earnings-per-share guidance to $4.90 to $5.10
- Are Gene Therapy Stocks The Market’s Next Big Winners?
During the quarter, BioMarin completed its acquisition of Amicus Therapeutics, adding two commercial rare-disease products: Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease. Mueller characterized the products as high-growth assets that can benefit from BioMarin’s larger global infrastructure
BioMarin estimates peak revenue of $1.4 billion for Galafold and $1.2 billion for Pombiliti and Opfolda, with those opportunities expected in the mid- to late 2030s, respectively. The company also expects to realize synergies equal to roughly 50% of Amicus’ legacy operating-cost base, primarily through general and administrative expenses and other support functions
Mueller said BioMarin is preserving and investing in the acquired sales and marketing organization rather than pursuing aggressive commercial cost reductions. “These products are in their high-growth phase,” he said, adding that maintaining customer-facing capabilities is important to sustaining growth
Ad Profits Run
Your $29.97 book is free today
Why Some Traders Skip Stocks EntirelynnYou don’t need a big account to trade options.nnIn fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up.nnThis free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.
Normally $29.97. Today it’s free. Grab your copy now.
